175. J Nanobiotechnology. 2018 Feb 21;16(1):18. doi: 10.1186/s12951-018-0341-6.Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.Alric C(1), Hervé-Aubert K(1), Aubrey N(2), Melouk S(1), Lajoie L(3), Même W(4), Même S(4), Courbebaisse Y(5), Ignatova AA(6)(7), Feofanov AV(6)(7), Chourpa I(1),Allard-Vannier E(8).Author information: (1)EA6295 'Nanomédicaments et Nanosondes', Université de Tours, 37200, Tours,France.(2)ISP, Université de Tours, INRA, UMR 1282, Equipe BIOMédicamentsAnti-Parasitaires, 37380, Nouzilly, France.(3)GICC 'Groupe Innovation et Ciblage Cellulaire', Université de Tours, EquipeFRAME - Fc Récepteurs, Anticorps et MicroEnvironnement, 37032, Tours, France.(4)CBM, CNRS, UPR4301, Equipe Complexes Métalliques et IRM pour applicationsbiomédicales, 45071, Orléans, France.(5)Bertin Pharma Orléans, 45071, Orléans, France.(6)Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy ofSciences, ul. Miklukho-Maklaya, 16/10, Moscow, 117997, Russia.(7)Biological Faculty, Lomonosov Moscow State University, Vorobyevi Gori 1,Moscow, 119992, Russia.(8)EA6295 'Nanomédicaments et Nanosondes', Université de Tours, 37200, Tours,France. emilie.allard@univ-tours.fr.BACKGROUND: Recent advances in nanomedicine have shown the great interest ofactive targeting associated to nanoparticles. Single chain variable fragments(scFv) of disease-specific antibodies are very promising targeting entitiesbecause they are small, not immunogenic and able to bind their specific antigens.The present paper is devoted to biological properties in vitro and in vivo offluorescent and pegylated iron oxide nanoparticles (SPIONs-Cy-PEG-scFv)functionalized with scFv targeting Human Epithelial growth Receptor 2 (HER2).RESULTS: Thanks to a site-selective scFv conjugation, the resultant nanoprobesdemonstrated high affinity and specific binding to HER2 breast cancer cells. The cellular uptake of SPIONs-Cy-PEG-scFv was threefold higher than that foruntargeted PEGylated iron oxide nanoparticles (SPIONs-Cy-PEG) and is correlatedto the expression of HER2 on cells. In vivo, the decrease of MR signals in HER2+ xenograft tumor is about 30% at 24 h after the injection.CONCLUSIONS: These results all indicate that SPIONs-Cy-PEG-scFv are relevanttumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2overexpressing breast tumor.DOI: 10.1186/s12951-018-0341-6 PMCID: PMC5820783PMID: 29466990 